birtamimab

Prothena is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies for diseases caused by protein dysregulation. The company's pipeline includes programs targeting neurodegenerative and peripheral amyloid diseases, such as Alzheimer's disease, Parkinson's disease, and AL amyloidosis. Their lead candidate, birtamimab, is a monoclonal antibody currently in Phase 3 clinical trials for the treatment of AL amyloidosis. Prothena leverages its expertise in protein misfolding and cell adhesion to develop potentially disease-modifying therapies. The company maintains significant partnerships with major pharmaceutical firms like Bristol Myers Squibb, Roche, and Novo Nordisk.